EEPARTMENT OF HEALTH AND HUMAN SERVICES 
PUBLIC HEALTH SERVICE 
NATIONAL INSTnUTES OP HEALTH 
RECOMBINANT CWA ADVISORY COMMITTEE 
MINUTES CF MEBTINGI 
APRIL 23-24, 1981 
The Recxx±»inant ENA Advisory Ccnmittee (RAC) was convened for its twenty-second 
meeting at 9:00 a.m. on ^^il 23, 1981, in Conference Room 10, Building 31C, 
National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20205. 
Mr, Ray Ttiomton (Chairman), President, Arkansas State University, presided. 
In accordance with Public Law 92-463, the meeting was c^n to the public from 
9:00 a.m, to 4:30 p.m. on April 23, and from 8:30 a.m. to adjournment at 
1:25 p.m, on /^il 24. The meeting was closed to the public from 4:30 p.m. 
to 6:00 p.m. on il^ril 23 for the review of proposals involving proprietary 
information. 
Committee manbers present for all or part of the meeting were ; 
Dr. David Baltimore; Dr. Kenneth Bems; Dr. Winston Brill; Dr. Allan Campbell; 
Mrs. Zelma Cason; Dr. Nina Fedoroff; Dr. Richard Goldstein; Dr. Susan Gottesman; 
Dr. Jean Harris; Dr. King Holmes; Ms. Patricia King; Dr. Sheldon Krimsky; 
Dr, Myron Levine; Dr. Werner Maas; Dr. James Mason; Dr, Gerard McGarrity; 
Dr. Robert McKinney; Dr. Elena Nightingale; Dr. Richard Novick; Dr. Ramon Pinon; 
Dr. John Scandalios; Dr. Luther Williams; and Dr. William J, Gartland, Jr., 
Executive Secretary. 
A Committee roster is attached. (Attachment I) 
The following ad hoc consultants to the Committee were present ; 
Dr. Edward A. Adelberg, Yale University; Dr. D. Michael Gill, Tufts University. 
The following non-voting members and liaison representatives were present ; 
Dr. Charlotte Bell, U.S. Department of Justice; Dr. Chia T. Chen, OSHA, U.S. 
Department of Labor; Dr. George Duda, U.S. Department of Energy; Dr. Timothy J. 
Henry, Food and Drug Mministration; Dr. -Herman Lewis, National Science Founda- 
tion; Mr, Seth Pauker, National Institute for Occupational Safety and Health; 
^The RAC is advisory to the NIH, and its recommendations should not be 
considered as final and accepted. The Office of Recombinant ENA Activities 
should be consulted for NIH policy on specific issues. 
[ 90 ] 
